AnaptysBio Inc
ANAB
View Detailed Chart
49.730USD
+1.830+3.82%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.37BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+3.82%
5 Days
+4.89%
1 Month
+13.25%
6 Months
+120.63%
Year to Date
+2.58%
1 Year
+209.27%
View Detailed Chart
TradingKey Stock Score of AnaptysBio Inc
Currency: USD Updated: 2026-02-06Key Insights
AnaptysBio Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 11 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 64.58.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
AnaptysBio Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
AnaptysBio Inc Highlights
StrengthsRisks
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 787.33% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 91.28M.
Undervalued
The company’s latest PE is -17.64, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 31.62M shares, increasing 0.03% quarter-over-quarter.
Held by Paul Tudor Jones
Star Investor Paul Tudor Jones holds 13.87K shares of this stock.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
64.583
Target Price
+34.83%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
AnaptysBio Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
AnaptysBio Inc Info
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.
Ticker SymbolANAB
CompanyAnaptysBio Inc
CEOFaga (Daniel R)
Websitehttps://www.anaptysbio.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68951.090
-1019.040 (-1.46%)
282.580
+22.390 (+8.61%)
2034.300
-17.430 (-0.85%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
